Daniel Rizzo
Jefferies LLC, Research Division
Good afternoon. I am Dan Rizzo with Jefferies Equity Research. Up next, we have Aptar Group. And today with us today, we have CEO, Stephan Tanda; CFO, Vanessa Kanu; Gael Touya, who is Aptar Pharma President; and Mary Skafidas, who is SVP of Investor Relations. We’re going to have a quick presentation about 15, 20 minutes. And afterwards, there will be time for questions.
So with that, I’ll turn it over to Stephan for the presentation.
Stephan Tanda
President, CEO & Executive Director
Thank you, Dan, and good afternoon, everybody. I got the great energetic after lunch hour. So welcome to Aptar in 25 minutes. For those of you not familiar with the company, we’ve been around for about 80 years, public for 35 years. And today, pharma is really the driving force of our company with almost 70% of EBITDA. And the Pharma business is really all about proprietary drug delivery devices, predominantly drug delivery through the nose or inhalation, but also ophthalmic and dermal and we’ll spend quite some time on it.
We also have a beauty business and the closure business. So broadly serve demographically advantaged end users, all the things you would think about, aging population, health and wellness and the drug application we serve are predominantly chronic disease treatment like asthma, COPD, allergic rhinitis, medicines that people take every day. We report out in 3 reporting segments, if you want the verticals here, but we manage the company really by technology platforms that you see here. Fundamentally, the core industrial processes that we
